CDRENYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Cadre Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$27.07+0.69 (+2.62%)
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- 33.4
- Dividend yield
- 1.40%
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
42.5%+4.7 pts over 5 years
Operating margin
11.0%−1.3 pts over 5 years
Net margin
7.2%−2.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +7.5% | +10.1% | +8.6% | – | |
| Gross profit | +11.2% | +13.9% | +11.2% | – | |
| Operating income | +0.9% | +59.1% | +6.2% | – | |
| Net income | +22.2% | +96.5% | +2.8% | – | |
| EPS, diluted | +13.3% | +85.4% | -6.1% | – | |
| Free cash flow | +117.7% | +10.7% | +6.9% | – | |
| Dividend per share | +8.6% | +68.1% | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -363.3% | 14.0% | |
| Return on assets | – | – | 6.2% | |
| Current ratio | – | 1.88 | 3.50 | |
| Debt to equity | – | 24.44 | 0.97 | |
| Net debt to EBITDA | – | 3.31× | 2.14× | |
| Interest coverage | – | 2.0× | – | |
| Inventory turnover | – | – | 3.8× | |
| Capex to revenue | – | 1.2% | 1.1% | |
| Diluted shares | – | 27M | 43M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cadre generated $255.19M from operations and spent $92.24M on capital expenditure, dividends and share buybacks. 29% of that went back into the business.
Generated
$255.19M
Used
$92.24M
Capital expenditure$26.58M29%Dividends$65.66M71%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin7.2%
×Asset turnover0.86×
×Equity multiplier2.26×
=Return on equity, FY202514.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 7.2% | 0.86× | 2.26× | 14.0% |
| FY2024 | 6.4% | 1.05× | 2.13× | 14.2% |
| FY2023 | 8.0% | 1.17× | 2.27× | 21.3% |
| FY2022 | 1.3% | 1.30× | 2.76× | 4.6% |
| FY2021 | 3.0% | 1.44× | 6.10× | 26.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$44.14M
- Cash generatingOperating cash flow above zero$63.71M
- Return on assets improvedROA up on the prior year8.4% → 6.8%
- Earnings backed by cashOperating cash flow above net income$63.71M vs $44.14M
- Less leverageLong-term debt to assets fell32.5% → 37.8%
- Better liquidityCurrent ratio rose3.48 → 3.50
- No dilutionShare count did not rise40M → 43M
- Gross margin improvedGross margin up on the prior year41.14% → 42.54%
- More efficientAsset turnover rose1.32 → 0.94